Trial Profile
Phase II trial of IMGN 529 in patients with relapsed/refractory diffuse large B-cell lymphoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2015
Price :
$35
*
At a glance
- Drugs Naratuximab emtansine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors ImmunoGen
- 14 Jan 2015 New trial record
- 11 Jan 2015 This study is expected to be initiated in the second quarter of 2015, according to an ImmunoGen media release.